Prostate Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

ASTRO 2020: Relugolix Versus Leuprolide for Localized and Recurrent Prostate Cancers
ASTRO 2020: Long-Term Follow-up With Low–Dose-Rate Prostate Brachytherapy
Prostate Cancer Prevalence in Men With Li-Fraumeni Syndrome
ASTRO 2020: Metastasis-Free Survival as Surrogate for Overall Survival in Recurrent Prostate Cancer
Is Increased Adiposity Causally Protective for Prostate Cancer?
ASTRO 2020: Using Fluciclovine PET Imaging to Guide Prostate Cancer Radiotherapy
ASTRO 2020: Hypofractionated Photon Versus Proton Therapy for Prostate Cancer
SARS-CoV-2 and Prostate Cancer: Is ADT Protective Against Infection?
Darolutamide in Treatment of Nonmetastatic Prostate Cancer: Outcomes Update From ARAMIS
Advanced Prostate Cancer: Role of Advanced Practitioners in Management
High-Risk Prostate Cancer: Three-Tiered Classification System Under Study
ESMO 2020: Talazoparib in Men With Metastatic Prostate Cancer and DNA Damage Response Alterations
Prostate Cancer and COVID-19: Delay in Time to Biopsy and Pathologic Findings
Role of ADT in Efficacy of Docetaxel in Metastatic Castration-Resistant Prostate Cancer
ESMO 2020: Adding Pembrolizumab After Enzalutamide Failure in Prostate Cancer
How Exercise May Impact Natural Killer Cells in Patients With Prostate Cancer
ESMO 2020: Survival Analysis From PROfound Trial in Metastatic Prostate Cancer
ESMO 2020: Ipatasertib Plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer and COVID-19: Prioritization Strategies for Disease Management
Association Between Human Papillomaviruses and Prostate Cancer?
Prostate Cancer and COVID-19: Is Hormonal Therapy a Protective or Risk Factor?
Biologic Differences in Prostate Tumors in Men of African Ancestry: Clinical Implications
Pan-Tumor Liquid Biopsy Test Approved by FDA as Companion Diagnostic for Rucaparib
BET Bromodomain Inhibitor Plus Enzalutamide in Metastatic Prostate Cancer
Prostate Cancer and COVID-19: Does Timing of Treatment Affect Survival Outcomes?
Life Course of BMI and Risk of Aggressive Prostate Cancer
Combining Brachytherapy With Immunotherapy for High-Risk Prostate Cancer
Consensus Conference Offers Guidance on Germline Testing for Prostate Cancer
EUPROMS Study of Quality of Life in Men Treated for Prostate Cancer
Olaparib Monotherapy for Advanced Prostate Cancer With Mutations: TAPUR Update
Darolutamide Plus ADT for Nonmetastatic Prostate Cancer: Final Update From ARAMIS
Early Results With Alpha Emitter for Metastatic Castration-Resistant Prostate Cancer
AACR COVID-19: Hormonal Therapy and Severe Virus-Related Outcomes in Prostate Cancer
Leuprolide Plus Apalutamide as Neoadjuvant Therapy for Prostate Cancer
AACR COVID-19: Recent Trends in Screening for Prostate Cancer
Updated AUA, ASTRO, and SUO Guideline for Management of Advanced Prostate Cancer
Circulating Tumor DNA Analyses in Metastatic Castration-Resistant Prostate Cancer
AACR II: Pain Management in Veterans With Metastatic Castration-Resistant Prostate Cancer
Can Findings on PSMA PET/CT Alter Management in Recurrent Prostate Cancer?
Do Men Treated With Enzalutamide for Prostate Cancer PROSPER? Final Survival Results
PDK4 Gene May Serve as Prognostic Marker in Prostate Cancer
Bipolar Androgen Therapy in Metastatic Castration-Resistant Prostate Cancer
SPARTAN Final Results on Apalutamide in Castration-Resistant Prostate Cancer
Resensitization of Prostate Cancer With Bipolar Androgen Therapy
AACR II: Is Grape Seed Extract of Benefit to Men With Prostate Cancer?
AACR II: Therapeutic Benefits of Yoga in Men Treated With Prostatectomy
Bridging the Racial Gap: Underrepresentation of Minorities in Prostate Clinical Trials
ASCO20: Genetic Profiling to Guide Targeted Screening for Prostate Cancer
ASCO20: Phase I Trial of ARV-110 for Metastatic Castration-Resistant Prostate Cancer
Targeting Metabolic Pathway in Treating Aggressive Prostate Tumors
ASCO20: Cabozantinib Plus Atezolizumab for Castration-Resistant Prostate Cancer
ASCO20: Radical Prostatectomy After ADT for High-Risk Prostate Cancer
Radiotherapies Plus Androgen Deprivation After Surgery for High-Risk Prostate Cancer
ASCO20: Novel Imaging Modality Under Study in Biochemically Recurrent Prostate Cancer
ASCO20: LuPSMA Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
ASCO20: Predicting Outcomes in Metastatic Prostate Cancer With CTC Counts
ASCO20: HERO Trial Compares Relugolix and Leuprolide Acetate in Advanced Prostate Cancer


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.